In the News
September 03, 2014
Time for our annual review of the Inc. 5000 list, Inc. magazine’s ranking of the fastest-growing private U.S. companies. Once again, the Inc. 5000 list highlights the boom in specialty drug dispensing. The 2014 list, which is based upon revenue growth through 2013, includes 13 specialty pharmacies. The pharmacies and key stats are listed below. Total revenues for the group were $3.1 billion. Diplomat, with $1.5 billion in revenues, accounted for half of the total.
August 28, 2014
This summer, Avella Specialty Pharmacy launched a new patient portal and a stand-alone mobile application that allows customers to manage their prescriptions from their mobile phone. By logging into either of these secure tools, patients can quickly and easily request prescription refills, view their prescription history and transfer prescriptions between pharmacies. Not only do these new tools offer greater convenience, they also help Avella’s customers maintain their health and safety by providing access to refill reminders and important information about medications.
August 27, 2014
As of January 2014, 90% of American adults own a cell phone, and 58% of adults have a smartphone, according to a study by Pew Research (http://bit.ly/1fvWYrL). In fact, as of 2011, there are more mobile phones, tablets and other wireless devices in the United States than there are people—a trend that could soon have a profound effect on the services that specialty pharmacy provides to patients.
August 13, 2014
Phoenix—Recent legislation helps providers identify pharmacies that maintain current good manufacturing practices (cGMPs), but what does that mean? And how can a facility ensure that it is dealing with a good compounding pharmacy?
July 08, 2014
Interview with Rebecca M. Shanahan, CEO of Avella Specialty Pharmacy, a speaker at IIR's upcoming Annual Summit for Oncology Management, July 21-23, in Philadelphia.
June 29, 2014
Rebecca Shanahan spends a lot of her time dealing with orphans. Not people: drugs. "Orphan drugs are those needed by a small population of patients, usually 6,000 or fewer," says Shanahan, CEO of Avella Specialty Pharmacy. "The challenge for drug manufacturers is that they have to put all of the effort into research, development and testing. Often times, the cost of getting the drug from its inception to market requires a disproportionate expense as compared to what the return on the investment would be."
May 23, 2014
Donna M. Smith, Pharm.D., director of clinical affairs at Avella Specialty Pharmacy discusses developments in the treatment of lung cancer that specialty pharmacies need to be aware of. This video was shot at the Armada Health Care 2014 Specialty Pharmacy Summit and Expo in Las Vegas, Nevada.
May 20, 2014
Emerging therapies and the role of specialty pharmacies in the treatment of non-small cell lung cancer were discussed during a continuing education session at the annual Armada summit.
May 12, 2014
CEO of Avella Specialty Pharmacy Rebecca M. Shanahan, Esq., discusses how specialty pharmacies can best manage the rising cost of specialty drugs to improve outcomes for patients. This video was shot at the Armada Health Care 2014 Specialty Pharmacy Summit and Expo in Las Vegas, Nevada.
May 01, 2014
Patient care, communication and coordination take center stage as Diplomat Specialty Pharmacy, Avella Specialty Pharmacy, Amber Pharmacy and 32 other select companies begin distributing apremilast, the first FDA-approved oral therapy for psoriatic arthritis.
From the Avella Blog
October 03, 2014
Avella is proud to introduce the National Psoriasis Foundation as a valuable dermatology resource for our patients and providers. Founded in 1968, the National Psoriasis Foundation has evolved to become the leading patient advocacy group for the 7.5 million Americans living with psoriasis and psoriatic arthritis. As emerging research continues to demonstrate the serious effects of these chronic autoimmune diseases, the most important priority of the National Psoriasis Foundation is to find a ...